FIELD: pharmacology.
SUBSTANCE: presented lactic acid bacterium contains a unit of polycistronic expression, the said polycistronic expression unit containing a gene endogenous to the said lactic acid bacterium (endogenous gene) and one or more genes exogenous to the said lactic acid bacterium (exogenous genes). The said endogenous gene and one or more exogenous genes are under transcriptional control of a promoter endogenous to the said lactic acid bacterium.
EFFECT: inventions provide high expression levels of heterologous proteins and can be used in medicine.
52 cl, 23 dwg, 8 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYCISTRONIC EXPRESSION SYSTEM FOR BACTERIA | 2012 |
|
RU2766157C2 |
| GENETICALLY MODIFIED BACTERIA STABLY EXPRESSING IL-10 AND INSULIN | 2017 |
|
RU2768027C2 |
| MUCOADHESIVE MICROORGANISM | 2017 |
|
RU2762940C2 |
| Lactococcus PROMOTORS AND THEIR APPLICATION | 2008 |
|
RU2495129C2 |
| MODIFIED GRAM-POSITIVE BACTERIA AND THEIR APPLICATIONS | 2012 |
|
RU2773435C2 |
| MODIFIED GRAM POSITIVE BACTERIA AND USES THEREOF | 2012 |
|
RU2653757C2 |
| RECOMBINANT PROBIOTIC BACTERIA | 2015 |
|
RU2723324C2 |
| CHLORIDE-INDUCED PROKARYOTIC EXPRESSION SYSTEM | 2019 |
|
RU2812766C2 |
| COMPOSITIONS AND METHODS FOR TREATING TYPE 1 DIABETES | 2017 |
|
RU2760997C2 |
| XYLOSE ISOMERASE-EXPRESSING MICROORGANISM | 2009 |
|
RU2553537C2 |
